Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 3;15(1):56.
doi: 10.1038/s41408-025-01270-4.

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

Naseema Gangat  1 , Ayalew Tefferi  2
Affiliations
Editorial

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

Naseema Gangat et al. Blood Cancer J. .

Abstract

Venotoclax schedule in acute myeloid leukemia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NG has served on the Advisory Board for Agio and DISC Medicine.

Figures

None
Venotoclax schedule in acute myeloid leukemia
See this image and copyright information in PMC

References

    1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - PubMed
    1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025. 10.1002/ajh.27625. Online ahead of print. - PMC - PubMed
    1. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881–92. - PubMed
    1. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–75. - PMC - PubMed
    1. Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56:226–9. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources